The novel dual D2 dopamine receptor, β2 -adrenoceptor agonist Viozan™ (AR-C68397AA) is well tolerated in a dog model Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001
The antitussive effects of alpha7 (a7) nicotinic receptor agonists Source: International Congress 2017 – Novel studies on bronchodilators and cough Year: 2017
A new ultra-potent vanilloid receptor 1 (VR1) antagonist abates capsaicin and citric acid induced cough Source: Eur Respir J 2002; 20: Suppl. 38, 190s Year: 2002
In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407Source: Eur Respir J 2007; 30: Suppl. 51, 26s Year: 2007
The triple neurokinin receptor antagonist CS-003 inhibits neurokinin A (NKA)-induced bronchoconstriction in patients with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 415s Year: 2003
Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004
Modulation of cortical and respiratory activity by 5-HT2 receptor agonist in the rat Source: Annual Congress 2008 - Control of breathing and respiratory disorders during sleep Year: 2008
Pharmacological activities of R-113281, a triple NK1 /NK2 /NK3 neurokinin receptor antagonist Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
The novel dual D2 dopamine receptor, β2 -adrenoceptor agonist, Viozan™ (AR-C68397AA) improves quality of life and perception of efficacy Source: Eur Respir J 2001; 18: Suppl. 33, 3s Year: 2001
In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonistSource: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007
Novel triple neurokinin receptors antagonist CS-003 strongly inhibits neurokinin related responses Source: Eur Respir J 2006; 28: Suppl. 50, 115s Year: 2006
The effect of leukotrienes and their receptor antagonists on calcium signalling in the cough receptors transient receptor potential ankyrin 1 (TRPA1) and vanilloid 1 (TRPV1) Source: Annual Congress 2010 - Models of airways disease Year: 2010
Nicotinic alpha-7 receptor stimulation (a7nAChR) inhibited NF-kB/STAT3/SOCS3 pathways in a murine model of asthma. Source: International Congress 2017 – Novel mechanisms and treatments for asthma Year: 2017
Vasopressin is involved in endothelin receptor antagonist-induced fluid retention in rat. Differential effect of selective ETA and dual ETA/ETB receptor antagonists Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis Source: International Congress 2019 – Damage and remodelling in pulmonary fibrosis Year: 2019
Protease-activated receptor 2 (PAR2) stimulation potentiates citric acid induced cough by sensitising the vanilloid receptor-1 (TRPV1) Source: Annual Congress 2003 - Novel drugs under development for the treatment of respiratory diseases Year: 2003
Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients Source: Eur Respir J 2004; 23: 76-81 Year: 2004
The cannabinoid receptor agonist, WIN 55,212-2, inhibits antigen-induced plasma extravasation in guinea pig airways Source: Annual Congress 2010 - Models of airways disease Year: 2010
The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan Source: Annual Congress 2010 - Airway smooth muscle cells Year: 2010
Distinct effects of the endothelin receptor antagonists PD 142893 (ET-A/B), BQ 788 (ET-B) and N-Ac-Trp-ET 1 Frg. 16-21 (ET-A) on oxidative stress-induced pulmonary hypertension in isolated rabbit lungs Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001